Clive Meanwell, MD
Chairman, Managing Partner
Clive Meanwell founded Population Health Partners in 2020 and has served as the Executive Chairman and a Managing Partner since its inception.
Clive was deeply involved in the development and commercialization of many biopharmaceutical products – including Neupogen®,a leading oncology product, Angiomax®, the top-selling anticoagulant for cardiac procedures in US hospitals, and Leqvio® for cholesterol lowering – throughout a career spanning four decades.
Clive is also Vice Chairman of BB Biotech, a listed investment corporation which invests in mainly public biotech firms, and a director of Fractyl Health, Comanche Biopharma, EQRx, and Hugo Health.
After a series of senior executive positions with Roche in Switzerland and the US in product development, regulatory affairs, and marketing, he founded, built, and led The Medicines Company, a biopharmaceutical company focused on acute hospital care, before pivoting the firm to the population health challenges of cardiovascular disease. The Medicines Company was sold to Novartis for $9.7 billion in January 2020.
Clive trained in medicine, with post-graduate specialization in cancer research, clinical trials, statistics, and epidemiology. He holds MB ChB and MD cum laude degrees from the University of Birmingham, UK.
